Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Bak-Jensen
Henriette Husum Bak-Jensen, Copenhagen S DK
| Patent application number | Description | Published |
|---|---|---|
| 20090270453 | ANTI-MANIC EFFECTIVE DOSES OF SERTINDOLE - The present invention relates to uses of an anti-manic effective dose sertindole in the preparation of a pharmaceutical composition for the treatment of mania, and to methods of treating mania comprising administering said effective dose of sertindole. In separate aspects of the invention, said uses and methods are directed to treating manic episodes. | 10-29-2009 |
Kristian S. Bak-Jensen, Copenhagen DK
| Patent application number | Description | Published |
|---|---|---|
| 20100135998 | COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS - Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders. | 06-03-2010 |
Kristian Sass Bak-Jensen, Kobenhavn V DK
| Patent application number | Description | Published |
|---|---|---|
| 20120035099 | FGF21 ANALOGUES AND DERIVATIVES - Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process. | 02-09-2012 |
Kristían Sass Bak-Jensen, Kobenhavn V DE
| Patent application number | Description | Published |
|---|---|---|
| 20100216715 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use - The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability. | 08-26-2010 |
Kristían Sass Bak-Jensen, Kobenhavn V DE
| Patent application number | Description | Published |
|---|---|---|
| 20100216715 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use - The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability. | 08-26-2010 |